Add BrightSurf on Google Email

AI helps to open new routes to earlier diagnosis and treatment of Crohn’s disease

Researchers combined AI, genetics, and gut microbiome analysis to shed light on intestinal fibrosis in Crohn's disease. They identified a shared set of 43 key genes linked to disease progression and found that bowel fibrosis is driven by ongoing immune activation, damage to the intestinal lining, and changes in gut bacteria.

SourceUniversity of Birmingham·JournalFrontiers in Artificial Intelligence·TypeExperimental study·DateAug 12, 2026

Patients with IBD face elevated risk of psychiatric disorders

Researchers found that patients with inflammatory bowel disease (IBD) are at a significantly higher risk of developing psychiatric disorders, particularly depression and anxiety. The study highlights the importance of early screening and integration of psychological care into routine IBD management to improve quality of life.

SourceAmerican Gastroenterological Association·JournalClinical Gastroenterology and Hepatology·DateAug 5, 2026

Mount Sinai study detects immune changes up to 10 years before inflammatory bowel disease is diagnosed

Researchers identified unique antibody signatures against viruses and bacteria in nearly 2,000 blood samples collected over a decade, showing immune system changes years before diagnosis. The study supports the theory of molecular mimicry and provides an important framework for understanding IBD's earliest stages.

Research highlighting estrogen link could explain why women are more likely to suffer from Crohn’s

Scientists discovered a direct link between estrogen and gut inflammation in Crohn's disease. The study used zebrafish models to show that estrogen signalling plays a crucial role in maintaining normal gut health. This finding could lead to more personalized approaches to treatment, especially for females affected by the disease.

SourceUniversity of Bath·JournalPLOS Biology·TypeExperimental study·DateJun 23, 2026

Investigators identify blood protein signature for non-invasive diagnosis of pediatric inflammatory bowel disease

A team of researchers has identified a distinct blood protein pattern that can accurately diagnose pediatric inflammatory bowel disease and differentiate between its two main forms. The discovery, using proteomics technology, showed high accuracy in identifying IBD and distinguishing ulcerative colitis from Crohn's disease.

SourceMass General Brigham·JournalEBioMedicine·TypeSystematic review·DateJun 23, 2026

Decoding Inflammatory Bowel Disease – on a chip

A new study replicated patient- and sex-specific hallmarks of Inflammatory Bowel Disease (IBD) in a human organ chip, identifying stromal fibroblasts as key drivers of inflammation, fibrosis, and enhanced cancer risk. The model also recapitulated the impact of pregnancy hormones on IBD severity in female patients.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Biomedical Engineering·TypeExperimental study·DateMay 21, 2026

An experimental model reproduces creeping fat associated with Crohn's disease and facilitates its study

A new experimental rat model reproduces creeping fat in Crohn's disease, characterized by mesocolic adipose tissue hyperplasia with macroscopic, histological, immunological, and molecular similarities to human disease. The model supports the hypothesis that intestinal microbiota contributes to remodelling of mesenteric adipose tissue.

SourceGermans Trias i Pujol Research Institute·JournalInflammatory Bowel Diseases·TypeExperimental study·DateMar 11, 2026

Crohn’s & Colitis Foundation survey finds 93% of IBD community supports predictive testing and prevention strategies

A new survey by the Crohn's & Colitis Foundation found that 93% of people with inflammatory bowel disease (IBD) or at risk for it would be interested in a test to predict their risk of developing IBD. Lifestyle interventions, such as diet and exercise, were preferred over pharmaceutical approaches.

SourceCrohn's & Colitis Foundation of America·JournalCrohn s & Colitis 360·TypeSurvey·DateFeb 3, 2026

Insilico Medicine to present three abstracts at the 2026 Crohn’s & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411, a novel gut-restricted PHD1/2 inhibitor for inflammatory bowel disease

Insilico Medicine presents three abstracts at the 2026 Crohn's & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411. The first-in-human Phase 1 results show no serious adverse events or deaths reported, with a favorable pharmacokinetic profile supporting gut restriction.

A new diet option for mild-to-moderate Crohn’s disease

A new diet option has been shown to improve both physical symptoms and biological indicators of mild-to-moderate Crohn's disease. Participants in the fasting mimicking group experienced significant declines in fecal calprotectin, a protein indicating gut inflammation, and showed clinical benefits even after just one cycle.

SourceStanford Medicine·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJan 13, 2026

Lower prevalence of PSC among patients with IBD in Asia: Insights from a multinational study

A multinational study found PSC prevalence among Asian IBD patients to be markedly lower than in Western countries, associated with more favorable clinical outcomes. The proportion of asymptomatic PSC cases has increased due to improved imaging modality detection, allowing for early-stage diagnosis and reduced liver transplantation rates.

SourceUniversity of Tsukuba·JournalClinical Gastroenterology and Hepatology·DateDec 2, 2025

American Gastroenterological Association streamlines Crohn’s disease treatment guidance as new therapies expand options

The American Gastroenterological Association has released an updated clinical guideline on the pharmacological management of moderate-to-severe Crohn’s disease, recommending early use of high-efficacy therapies to improve patient outcomes. The guideline organizes treatments by efficacy to simplify decision-making for gastroenterologist...

SourceAmerican Gastroenterological Association·JournalGastroenterology·TypeNews article·DateNov 20, 2025

Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders

Researchers at UGA engineered a live bacterium to deliver Levodopa steadily from the gut to the brain, alleviating motor deficits in models of Parkinson's disease. This breakthrough could lead to fewer pills, steadier symptom control, and better quality of life for patients.

SourceUniversity of Georgia, College of Veterinary Medicine·JournalCell Host & Microbe·TypeRandomized controlled/clinical trial·DateNov 13, 2025

Mount Sinai’s Jean-Frédéric Colombel, MD, to deliver the 31st Anatomy Lesson in Amsterdam, highlighting global efforts to prevent and cure Crohn’s disease

Renowned gastroenterologist Jean-Frédéric Colombel, MD, will deliver the 31st Anatomy Lesson on November 20, exploring Mount Sinai's pioneering work in IBD prevention and treatment. His presentation aims to highlight the growing problem of immune diseases, including Crohn's disease.

Crohn’s & Colitis Foundation and international partners launch GLIDE: An integrated global registry to advance IBD care

The Crohn's & Colitis Foundation has launched GLIDE, an integrated global registry to connect patient data from IBD registries worldwide. This initiative aims to accelerate insights into complex clinical questions, driving improvements in care for those living with Crohn's disease and ulcerative colitis.

Study suggests no link between antibiotic exposure and autoimmune diseases in children

A large-scale study published in PLOS Medicine found no association between early life antibiotic exposure and the development of autoimmune diseases in children. Researchers analyzed data from over 4 million Korean children and discovered no increased risk of Type 1 diabetes, Juvenile idiopathic arthritis, or other autoimmune conditions.

SourcePLOS·JournalPLOS Medicine·TypeObservational study·DateAug 21, 2025

Mount Sinai researchers uncover unique biological markers in patients with mild Crohn’s disease

A new study led by Mount Sinai researchers has identified distinct biological signatures in patients with mild Crohn's disease, which may help avoid overtreatment and guide more personalized care. The findings suggest that these biomarkers can distinguish mild disease from more aggressive forms, potentially allowing for safer treatment...

Research collaboration charts global four-stage evolution of inflammatory bowel disease

Researchers from UCalgary and Chinese University of Hong Kong found that IBD progresses through four predictable epidemiological stages as it spreads globally. The study forecasts a major rise in IBD prevalence in Canada by 2045, with countries in North America, Europe, and Oceania reaching Stage 3 (compounding prevalence). Developing ...

SourceUniversity of Calgary·JournalNature·TypeMeta-analysis·DateApr 30, 2025

Study reveals stark racial disparities in IBD care across the united states

A new study published in the American Journal of Gastroenterology found significant disparities in healthcare utilization among racial and ethnic groups with inflammatory bowel disease (IBD) in the US. Black Americans over 65 had nearly 1.5 times higher use of emergency department services compared to White counterparts, while Asian an...

SourceCrohn's & Colitis Foundation of America·JournalThe American Journal of Gastroenterology·TypeData/statistical analysis·DateApr 1, 2025